Key Events This Week
3 Aug: Stock opens strong at Rs.1,594.60 (+1.79%) amid positive market sentiment
4 Aug: Sharp decline to Rs.1,542.15 (-3.29%) following profit booking
6 Aug: Upgrade to Buy rating by MarketsMOJO announced; stock rebounds to Rs.1,562.40 (+2.55%)
7 Aug: Minor correction to Rs.1,547.55 (-0.95%) closes the week
3 August 2026: Strong Opening Amid Positive Market Momentum
Venus Remedies began the week on a positive note, rallying 1.79% to close at Rs.1,594.60. This outperformance relative to the Sensex’s 0.82% gain reflected renewed investor interest, possibly driven by anticipation of upcoming quarterly results and valuation reassessments. The volume of 1,885 shares traded indicated moderate participation, setting a firm tone for the week.
4 August 2026: Sharp Correction on Profit Booking
The stock corrected sharply by 3.29% to Rs.1,542.15, underperforming the Sensex which declined marginally by 0.14%. Increased volume of 2,908 shares suggested active profit booking after the initial surge. This dip appeared to be a short-term reaction rather than a fundamental shift, as no adverse news emerged on this day.
6 August 2026: Upgrade to Buy Rating Spurs Recovery
MarketsMOJO upgraded Venus Remedies Ltd from 'Hold' to 'Buy' on 5 August 2026, citing strong valuation metrics and robust financial performance. This announcement catalysed a 2.55% rebound in the stock price to Rs.1,562.40, outperforming the Sensex’s 0.28% gain. The upgrade was underpinned by a significant improvement in valuation grades, with the company’s price-to-earnings ratio at 17.49, substantially lower than peers such as Hester Biosciences (PE 39) and NGL Fine Chem (PE 43.88).
Venus Remedies’ financial results for the quarter ending June 2026 revealed a remarkable 139.27% year-on-year net profit growth, with profit after tax for six months reaching ₹70.47 crores, up 130.29%. Operating profit expanded at an annualised rate of 56.81%, while net sales rose 31.95% to ₹438.26 crores. These figures underscore the company’s strong earnings momentum and operational efficiency.
Just announced: This Small Cap from Tyres & Allied with precise target price is our pick for the week. Get the pre-market insights that informed this selection!
- - Just announced pick
- - Pre-market insights shared
- - Tyres & Allied weekly focus
The upgrade also highlighted Venus Remedies’ attractive enterprise value multiples, including an EV to EBITDA ratio of 11.69 and an EV to EBIT ratio of 13.88, both indicating efficient earnings generation relative to enterprise value. The PEG ratio of 0.11 further signals undervaluation relative to rapid profit expansion, contrasting with peers whose PEG ratios range from 0.18 to 2.47.
Quality metrics such as return on capital employed (ROCE) at 21.23% and return on equity (ROE) at 15.49% affirm the company’s operational strength. The net-debt-free status enhances balance sheet resilience, reducing leverage risks amid sector volatility.
7 August 2026: Minor Pullback Amid Market Consolidation
Venus Remedies closed the week with a slight decline of 0.95% to Rs.1,547.55, marginally underperforming the Sensex’s 0.21% drop. The volume of 1,757 shares traded indicated moderate activity as investors digested the recent upgrade and strong earnings data. This minor correction is consistent with typical market consolidation following a significant rating change and earnings announcement.
Thinking about Venus Remedies Ltd? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this micro-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Weekly Price Performance: Venus Remedies vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-08-03 | Rs.1,594.60 | +1.79% | 36,985.17 | +0.82% |
| 2026-08-04 | Rs.1,542.15 | -3.29% | 36,933.47 | -0.14% |
| 2026-08-05 | Rs.1,523.55 | -1.21% | 37,074.66 | +0.38% |
| 2026-08-06 | Rs.1,562.40 | +2.55% | 37,177.57 | +0.28% |
| 2026-08-07 | Rs.1,547.55 | -0.95% | 37,099.57 | -0.21% |
Key Takeaways from the Week
Positive Signals: The MarketsMOJO upgrade to a Buy rating on 5 August 2026 was a pivotal event, reflecting Venus Remedies’ improved valuation and strong financial performance. The company’s low PE ratio of 17.49 and PEG ratio of 0.11 highlight its undervaluation relative to earnings growth, while robust profit growth of over 130% year-on-year confirms operational strength. Quality metrics such as ROCE of 21.23% and ROE of 15.49% further validate efficient capital utilisation.
Cautionary Notes: Despite the upgrade, the stock underperformed the Sensex over the week, declining 1.22% against a 1.13% benchmark gain. The micro-cap status and absence of domestic mutual fund holdings may contribute to higher volatility and limited institutional support. The 52-week trading range from Rs.423.70 to Rs.2,043.15 indicates significant price swings, suggesting investors should be mindful of liquidity and market fluctuations.
Conclusion: A Week of Valuation Reassessment Amid Market Volatility
Venus Remedies Ltd’s week was defined by a significant upgrade in investment rating, driven by improved valuation metrics and strong quarterly earnings growth. While the stock faced short-term price corrections and ended the week slightly lower, the fundamental improvements position it favourably within the Pharmaceuticals & Biotechnology sector. The company’s attractive PE and PEG ratios, combined with solid profitability and a net-debt-free balance sheet, offer a compelling case for investors seeking growth opportunities in a micro-cap stock.
However, the divergence from the Sensex’s positive performance and the inherent risks associated with micro-cap stocks warrant a cautious approach. Overall, the week’s events underscore a renewed price attractiveness for Venus Remedies, supported by robust financials and a positive reassessment by market analysts.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
